What is driving the particular strength in China, especially given the industrial lean, and how much is it related to the mid-market strategy in Product Inspection?

The strength in China is primarily from core industrial automation, driven by investments across many end markets, and also from the pharma space due to Pharmacopoeia changes, leading to demand for high-end balances. It is not primarily driven by the Product Inspection business. “the strength is not coming necessarily out of the product inspection business is really the core automation business in our core industry business. There is a really nice momentum. There's a lot of investment going on in automation in China across many of the end markets.”

Can you elaborate on the increased activity in your pipeline supporting improved growth in the back half, beyond the typical 1.5 months of backlog?

Management sees positive indicators in their internal pipeline KPIs, which, combined with improving external global economic indicators, gives them confidence in second-half growth. They acknowledge a slower start to the year due to geopolitics causing customer delays, but are not seeing cancellations and expect projects to convert. “But when we look at the funnel, we're -- we need to still convert those in the sales, but an absent things deteriorating on a geopolitical scale, we're actually feeling pretty good.”

How is the company managing costs amidst rising freight, oil, and input costs, and what is the sensitivity to these factors, especially considering tariff dynamics?

The company is highly focused on cost management, including fuel and input costs, leveraging its agile culture. They are also pursuing price mitigation. Guidance cautiously factors in these headwinds, largely offsetting a temporary benefit from lower IEEPA tariffs in Q2, with potential upside from mitigation efforts. “So the way we're kind of thinking about it is like, we'll have that benefit, we'll have some of these headwinds. And they probably are in a similar kind of a range. But on top of that, of course, we're going to look at trying to do some mitigation, which could be an upside here.”

MTD

Mettler Toledo International (MTD) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· May 8, 2026

Source: earnings call transcript

Executive summary

Mettler-Toledo Q1 FY26 — Strong EPS Growth Amidst Market Uncertainty

Mettler-Toledo delivered solid Q1 FY26 results, with strong adjusted EPS growth driven by margin initiatives and innovation, despite an increasingly uncertain market environment. The company reiterated its full-year sales guidance while raising its adjusted EPS outlook, reflecting confidence in second-half growth and productivity programs. Management highlighted investments in automation, digitalization, and onshoring as future growth drivers, alongside strong performance in China and bioprocessing.

Highlights

Adjusted EPS grew 9% year-over-year to $8.91, exceeding expectations.
Local currency sales increased 3%, with 1% growth excluding acquisitions, demonstrating resilience.
Service revenue grew 7% (5% excluding acquisitions), highlighting strong customer connection and recurring revenue.
China sales grew 4% in local currency, driven by Industrial business momentum, with full-year expectations raised to mid-single digits.
Product Inspection sales grew 5% (6% excluding acquisitions), benefiting from innovation and mid-market strategy.

Concerns

Gross margin decreased 80 basis points to 58.7% due to unfavorable foreign currency and acquisitions, and a 90 basis point tariff headwind.
Adjusted operating margin decreased 80 basis points to 26%, with tariffs reducing operating profit by 4%.
Laboratory sales were flat excluding acquisitions, impacted by soft demand from academia and biotech customers for pipettes, and delayed customer investments in Europe.
Core Industrial sales were flat excluding acquisitions, reflecting cautious purchasing patterns and customer delays due to geopolitical and macro uncertainty.
Free cash flow of $120 million was negatively impacted by $58 million higher tax payments compared to the prior year.

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 Local Currency Sales Growth	approximately 4% high materiality	FY26	High
Full-year 2026 Acquisition Contribution to Sales Growth	approximate 1.5% in the first half of the year and less than 8% for the full year medium materiality	FY26	High
Full-year 2026 Adjusted EPS	$46.30 to $46.95 high materiality	FY26	High
Full-year 2026 FX Impact on Sales Growth	2% benefit medium materiality	FY26	High
Full-year 2026 FX Impact on EPS	neutral medium materiality	FY26	High
Q2 2026 Local Currency Sales Growth	approximately 3% high materiality	Q2 · FY26	High
Q2 2026 Adjusted EPS	$10.70 to $10.85 high materiality	Q2 · FY26	High
Q2 2026 FX Impact on Sales	approximately 2% benefit medium materiality	Q2 · FY26	High
Q2 2026 FX Impact on Adjusted EPS	neutral medium materiality	Q2 · FY26	High
Full-year 2026 Total Amortization	approximately $78 million low materiality	FY26	High
Full-year 2026 Purchased Intangible Amortization (pretax)	approximately $28 million low materiality	FY26	High
Full-year 2026 Interest Expense	approximately $70 million low materiality	FY26	High
Full-year 2026 Other Income	approximately $25 million low materiality	FY26	High
Full-year 2026 Tax Rate (before discrete items)	19% medium materiality	FY26	High
Full-year 2026 Free Cash Flow	approximately $900 million high materiality	FY26	High
Full-year 2026 Share Repurchases	$825 million to $875 million high materiality	FY26	High
Full-year 2026 China Growth Expectations	mid-single digit medium materiality	FY26	High
Full-year 2026 Lab Sales Growth	low to mid-single digit medium materiality	FY26	Medium
Full-year 2026 Core Industrial Sales Growth	low to mid-single digit medium materiality	FY26	Medium
Full-year 2026 Product Inspection Sales Growth	mid-single digit medium materiality	FY26	Medium
Full-year 2026 Americas Sales Growth	low single digit medium materiality	FY26	Medium
Full-year 2026 Europe Sales Growth	low single digit medium materiality	FY26	Medium

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Laboratory Modest growth across most product categories, strong growth in bioprocessing, partially offset by decline in pipettes due to soft demand from academia and biotech. Expect gradual increase in activity in H2 FY26. Local currency sales ex-acquisitions: flatBioprocessing growth: strongPipettes growth: negative	—	flat	—	—
Industrial Overall strong growth, with Product Inspection benefiting from innovation and mid-market strategy. Core Industrial saw cautious purchasing patterns across most end markets. Industrial automation solutions are gaining momentum, especially in China. Local currency sales: +5%Local currency sales ex-acquisitions: +2%Core Industrial growth ex-acquisitions: flatProduct Inspection growth: +5%Product Inspection growth ex-acquisitions: +6%	—	+5%	—	—
Food Retail Strong sales growth against easy year comparisons. Business is lumpy, with strong growth in Europe offsetting declines in the U.S. in Q1.	—	+7%	—	—
Americas Growth in Lab and Product Inspection, but Core Industrial sales were soft due to customer delays and market uncertainty. Optimistic for growth in H2 FY26. Local currency sales ex-acquisitions: flatLab business growth: included strong bioprocessing growthProduct Inspection growth: strongCore Industrial sales: soft	—	+2%	—	—
Europe Strong growth in Product Inspection and Food Retail offset by softer market conditions, especially in the chemical sector due to higher energy costs.	—	+1%	—	—
Asia/Rest of World Good overall growth, with China showing strong momentum led by the Industrial business. Very good growth also seen in India, Southeast Asia, and other emerging markets. Local currency sales ex-acquisitions: +3%China growth: +4%Industrial business in China: led growthIndia growth: very goodSoutheast Asia growth: very good	—	+5%	—	—

Product announcements

Product	Type	Timeline
EasyMax advanced automated lab reactor	launch	recently
InMotion PX One autosampler	launch	recently
Low retention pipettes (PFAS-free)	launch	recently
X-ray solutions (expanded portfolio)	expansion	over the past year
M50 R-Series metal detectors	launch	recently

Deals & partnerships

Acquisitions Multiple acquisitions contributing to sales growth

Acquisitions are performing well, with teams focused on integration. The contribution to full-year sales guidance was increased from previous estimates.

Risks & headwinds

Increased uncertainty in macroeconomic environment Q1 FY26, continuing into Q2 FY26

Customer delays in Q1; impacted Core Industrial sales (flat ex-acquisitions)

Mitigation:Agility and strong execution of growth and margin expansion programs; confidence in H2 FY26 growth based on pipeline activity and improving global indicators.

Middle East conflict and higher global energy costs Q1 FY26, ongoing

Increased uncertainty in end markets; 4% gross headwind to operating profit and EPS in Q1; 90 bps headwind to gross margin in Q1; chemical sector softness in Europe

Mitigation:Mitigation through cost savings initiatives and additional pricing actions; cautious approach to guidance given dynamic environment.

Tariff headwind Q1 FY26, assumed to return to prior IEEPA rates mid-year

90 basis points headwind to gross margin in Q1; 4% gross headwind to operating profit and EPS in Q1

Mitigation:Guidance includes a temporary benefit from changes to U.S. import tariff rates in February; potential for tariff refunds from U.S. government (not included in guidance).

Soft demand from academia and biotech customers Q1 FY26

Negative growth in pipettes; Lab sales flat ex-acquisitions

Mitigation:Expect conditions to gradually improve throughout 2026 for Lab; strong bioprocessing growth; new product launches (e.g., PFAS-free pipettes) to compete better.

Lumpiness in Food Retail business Q1 FY26, expected in Q2 FY26 for Americas

Down double-digit in U.S. in Q1, offset by strong growth in Europe

Mitigation:New innovation in the last few years is well-received; team is competing well despite inherent lumpiness.

What to watch in Q2 FY26

Organic sales growth

H2 FY26

Current 1% LC ex-acquisitions (Q1 FY26)

Target Improved organic growth, particularly in Lab and Core Industrial

Why it matters

Management expects a stronger second half driven by pipeline conversion and improving macro conditions, which is critical for meeting full-year targets.

But we still feel very good about growth for the second half. I mean we'll talk a little bit more about that throughout the day. But I mean you kind of see a lot of positive indicators out there externally in terms of the PMIs. You see just global indicators looking positive. But when we look at our own pipeline, we also feel good about that as well.

Find out whether MTD delivers this. Inve re-checks your case every morning.

Q&A highlights

Why was the M&A contribution to sales guidance increased, implying a modest reduction in organic growth assumptions, and where is this organic softness concentrated (Lab vs. Industrial)?

Acquisition performance is strong, leading to an increased contribution. The modest organic reduction reflects first-half uncertainty, with expectations for stronger second-half growth. Lab is expected to be low single-digit organic, Core Industrial low single-digit organic (with China strength offsetting Western softness), and Product Inspection low single-digit organic reflecting Q1 strength. Americas is expected to be flattish in Q2 due to retail lumpiness, Europe to step up, and China's full-year growth expectations were raised to mid-single digits.

“So of course, that implies maybe a modest reduction in the organic number. I think that largely reflects a little bit of this uncertainty in the first half of the year. We're taking still a cautious approach to the second quarter just given the environment. But we still feel very good about growth for the second half.”

asked by Michael Ryskin · answered by Shawn Vadala

2 min read 6 chapters

Detailed narrative

Innovation and Product Portfolio Expansion

Mettler-Toledo continues to invest in innovation, launching new products across its segments. Recent introductions include the EasyMax advanced automated lab reactor for process development, the InMotion PX One autosampler for automated lab measurements, and PFAS-free low retention pipettes. In Industrial, the company expanded its X-ray solutions for mid-market coverage and introduced the M50 R-Series metal detector with 20% increased detection sensitivity, contributing to strong sales growth and market share gains in Product Inspection.

Strategic Focus on High-Growth Segments

The company is actively targeting high-growth segments such as bioprocessing, new energy, and semiconductor. Bioprocessing continues to show strong growth, driven by demand for automation and digitalization solutions, including bioreactor sensors and integrated intelligent sensor management systems. The semiconductor industry, particularly the ultra-pure water business within Process Analytics, is also performing extremely well, albeit representing a low single-digit contribution to total revenue.

Geographic Performance and China Momentum

Asia/Rest of World demonstrated good growth, with China growing 4% in Q1, primarily driven by the Industrial automation business and pharma investments related to Pharmacopoeia changes. This momentum led to an increased full-year growth expectation for China to mid-single digits.

Other emerging markets like India and Southeast Asia also showed very good growth. Americas sales were flat excluding acquisitions, while Europe saw softer conditions, particularly in the chemical sector due to higher energy costs.

Customer Behavior and Second Half Outlook

Management noted increased market uncertainty and customer delays in Q1, particularly in Western markets and the chemical sector, leading to a cautious approach for Q2 guidance. However, they expressed confidence in a stronger second half, citing improving global economic indicators, increased activity in their sales pipeline, and no observed order cancellations.

The anticipated recovery is expected to be driven by industrial automation solutions and a gradual improvement in lab conditions.

Service Business Strength

The service business continues to be a key differentiator and growth driver, with revenue increasing 7% (5% excluding acquisitions) in Q1. The company is actively pursuing a dedicated service growth initiative to increase the attach rate on its installed base and improve customer loyalty.

While connect rates vary by product (e.g., high for Product Inspection due to critical uptime needs), programs are in place to enhance service coverage across the portfolio.

Tariff Dynamics and Cost Management

Tariffs presented a 90 basis point headwind to gross margin and a 4% headwind to operating profit and EPS in Q1. The company's guidance includes a benefit from changes to U.S. import tariff rates in February, but assumes tariffs return to prior IEEPA levels mid-year.

Management is focused on mitigating higher costs from inflation and geopolitical events through cost savings and pricing actions, with potential upside if mitigation efforts outperform cautious guidance assumptions.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.